Re­gen­eron, Sanofi talk up po­ten­tial block­buster fran­chise as Dupix­ent sweeps in rhi­nos­i­nusi­tis PhI­II

A busy clin­i­cal team at Re­gen­eron $REGN and Sanofi $SNY has out­lined an­oth­er seg­ment on the al­ler­gic in­flam­ma­to­ry map that they plan to build their Dupix­ent king­dom up­on.

In two Phase III tri­als, in­ves­ti­ga­tors say, the mega-block­buster hope­ful de­liv­ered a clean sweep over chron­ic rhi­nos­i­nusi­tis with nasal polyps, clear­ing ob­struc­tion and shrink­ing ab­nor­mal tis­sue growth at a much high­er rate than place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER